ANN ARBOR, Mich., May 20, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced additional details regarding the significant advantages of the Company’s newly developed immortalized silk gland cell platform.

The Company recently announced the successful isolation and immortalization of silkworm posterior silk gland cells, a breakthrough designed to support next-generation recombinant protein manufacturing and advanced biomaterial production.

Kraig Labs’ technology differs significantly from conventional baculovirus insect cell expression systems commonly used throughout the biotechnology industry.

Traditional insect cell systems require cells to be infected and driven to produce a target protein until the cells are ultimately killed and destroyed to extract the protein. Once harvested, the process must begin again with a new batch of cells.

Kraig Labs’ system is designed around a fundamentally different approach.

Using natural exocytosis-based protein secretion pathway, the Company’s immortalized silk gland cells continuously produce and release target proteins into the surrounding culture media. Because the proteins are secreted naturally rather than retained inside the cells, they can potentially be harvested and purified more efficiently and repeatedly without disrupting or destroying the producer cells.

The Company believes this approach may offer several important manufacturing advantages.

Because the cells remain alive after protein collection, they can continue producing target proteins over extended production cycles. At the same time, collecting proteins directly from the surrounding media should reduce the need for more complex processing and purification steps typically associated with conventional intracellular production systems.

Together, these advantages may support faster production timelines, lower operating costs, improved scalability, and greater overall manufacturing efficiency.

“Our platform is designed to work with the silkworm’s natural biological systems,” said Kim Thompson, Founder and CEO of Kraig Labs. “Rather than destroying cells during protein recovery, our approach allows the cells to remain productive while continuously releasing target proteins into the surrounding media. We believe this technology could represent an important advancement in recombinant protein manufacturing.”

Kraig Labs believes its immortalized silk gland cell culture platform may represent an important evolution far beyond traditional systems by combining continuous protein production with natural protein secretion and simplified downstream recovery.

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., May 18, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced a biotechnology breakthrough with the successful creation of an immortalized silk gland cell line. The Company believes this technology could form the foundation for a next-generation biotechnology platform with potential applications in biopharmaceutical manufacturing, therapeutic peptides, biologically active proteins, and advanced biomaterials.

This breakthrough significantly expands the potential commercial reach of the Company’s core technologies beyond recombinant spider silk fibers and textiles. The Company’s research division continues to advance next-generation biotechnology platforms designed to unlock new commercial opportunities across multiple biotech sectors.

“This scientific achievement expands the Company’s technological reach and opens the potential for entirely new markets,” said Kim Thompson, Founder and CEO of Kraig Labs. “While our research team is expanding our portfolio and creating exciting new opportunities, management remains focused on the ongoing expansion of recombinant spider silk production and commercialization.”

As part of the scientific advancement announced today, the Company’s research team successfully isolated and established immortalized silk gland cells that demonstrate strong proliferative capacity, stable serial passaging, and robust long-term viability in vitro. Early testing has shown exceptionally strong recombinant protein expression and production capabilities, positioning the platform as a promising candidate for scalable industrial bioprocessing and recombinant protein manufacturing.

“The potential applications for this technology are extraordinarily broad,” said Xiaoli Zhang, Kraig Labs’ Chief Scientist. “We believe these immortalized silk gland cells could become the basis for a highly versatile biotechnology platform capable of supporting future work in therapeutics, vaccines, recombinant proteins, and next-generation biomaterials.”

The immortalized cell line has also demonstrated promising adaptability toward suspension culture systems, a critical requirement for large-scale industrial manufacturing and modern bioprocessing. This capability could allow the platform to integrate with conventional bioprocessing infrastructure and support more efficient, scalable, and cost-effective production systems.

“This achievement represents a major scientific milestone for our research team and highlights the depth of the biotechnology platform we have built,” added Thompson. “As we aggressively expand spider silk production operations, we are also investing in next-generation technologies that could open entirely new commercial markets for the Company. We believe this development has the potential to create opportunities in biotechnology sectors far beyond textiles. It is another example of our team’s leadership in this area of advanced biotechnology.”

The Company believes the unique biology of silkworm silk gland cells may provide important advantages for the production of specialized proteins and other biologically active compounds.

“This work demonstrates that Kraig Labs technological lead is not limited to advanced fibers and recombinant spider silks,” continued Thompson. “We are building broader biotechnology platforms centered on advanced genetic engineering, scalable biological manufacturing, and recombinant protein technologies.”

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., May 11, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced the successful commissioning of another recombinant spider silk production rearing center. The new facility is already in operation as part of the Company’s aggressive and strategic production expansion program.

The newly commissioned facility was brought online in less than 30 days. It is now supporting the Company’s April/May production cycle. Management expects this production cycle to set new records once again as Kraig Labs advances toward its goals for commercial-scale recombinant spider silk production.

The rapid deployment of this facility reflects the Company’s growing expertise in scaling production. Kraig Labs has standardized facility layouts, production workflows, staffing procedures, and operational systems. This approach allows the Company to quickly duplicate recombinant spider silk production capacity.

“This new rearing center is already expanding our production,” said Kim Thompson, CEO and Founder of Kraig Labs. “As we rapidly expand production, we are also increasing efficiency. Each new facility benefits from the experience gained from the previous production runs.”

The Company’s multi-facility production strategy is designed to increase both capacity and resiliency. By operating across multiple production centers, Kraig Labs creates operational redundancy and reduces concentration risk. The strategy also gives the Company greater flexibility as it rapidly scales toward commercial production targets.

According to the Company, the newest facility follows the same production architecture and operational framework already proven in prior facilities. This standardization allows new production centers to come online faster and more efficiently with each expansion cycle.

“This is exactly how we planned to scale this business,” continued Thompson. “We are no longer building one-off pilot operations to test system performance. We now have a system that has demonstrated the ability to produce recombinant spider silk at larger and larger scales. This new facility will play a central role in our production as we rapidly move to full commercial scale.”

The commissioning of this facility follows a series of recent production milestones. Earlier this year, the Company launched an aggressive scale-up initiative aimed at rapidly increasing recombinant spider silk output. Since then, Kraig Labs has expanded production capacity, deployed new production hybrids, increased cocoon processing throughput, and achieved consecutive record-setting production runs.

Management believes the April/May production cycle will represent another major step forward in the Company’s commercialization roadmap. Kraig Labs expects to continue deploying additional production capacity throughout 2026.

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Company Increases Production Capacity Again as it Advances toward Production Goals

ANN ARBOR, Mich., May 4, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has officially launched its next production cycle following the Company’s recent record-setting production run.

Earlier this month, the Company announced the successful production of nearly 1.8 metric tons of recombinant spider silk cocoons. 1.8 metric tons was the largest production run in the Company’s history. Today, Kraig Labs confirmed that its follow-on production cycle is underway. Consistent with the Company’s aggressive commercialization strategy, this cycle is expected to show a substantial increase over the previous cycle.

This next production expansion represents another major step in the Company’s carefully structured plan to rapidly scale output toward its long-term objective of producing more than 10 metric tons of recombinant spider silk cocoons in a single month.

“Our team continues to execute exactly as planned,” said Kim Thompson, Founder and CEO of Kraig Labs. “Each production cycle is delivering larger output, improved operational efficiency, and, with our quality control backstops working as designed, greater confidence in our ability to scale. We are systematically building toward our goal of exceeding 10 metric tons of production in a single month. Our team is hitting every mark as we scale output at a rapid pace.”

During senior management’s recent trip to the Company’s production operations in Southeast Asia, leadership worked directly with the production team to review current production infrastructure, staffing levels, and operational readiness to support this next phase of expansion.

That review included evaluating existing facilities, workforce requirements, and identifying additional opportunities to expand the Company’s operational footprint to support increasing production demands. The Company has already identified opportunities for additional facility expansion and expects to provide further updates as new facilities are brought online.

“Our recent operational review confirmed that our production team is prepared for this next level of scale,” added Thompson. “We continue to invest in the infrastructure, personnel, and production capacity required to meet the growing demand we anticipate for recombinant spider silk.”

The Company believes that expanding production capacity in parallel with downstream silk processing capabilities remains critical as it moves toward full commercialization of its recombinant spider silk technologies for technical textiles, luxury wear, performance apparel, and other high-performance material markets.

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., April 28, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced significant progress in the processing of its recently produced recombinant spider silk cocoons into reeled silk.

Earlier this month, Kraig Labs announced that it had successfully produced nearly 1.8 metric tons of recombinant spider silk cocoons, marking a historic milestone in the commercialization of spider silk. Today, the Company confirmed that the conversion of those cocoons into reeled silk fiber is now approximately 50% complete.

The silk currently being processed represents the largest volume of recombinant spider silk ever produced by Kraig Labs and is now moving through the next critical stage of commercialization. Once complete, this processing cycle will yield a substantial inventory of spider silk fiber ready to support ongoing product development initiatives and future commercial opportunities.

The accompanying image in this release highlights only a portion of the reeled silk already produced from this record-setting production run. As processing continues, the Company expects total silk output to increase significantly as the remaining cocoons are converted into reeled silk.

“This is exactly the kind of operational execution we have been working toward,” said Kim Thompson, Founder and CEO of Kraig Labs. “Producing nearly 1.8 metric tons of recombinant spider silk cocoons was a landmark achievement. Successfully converting that production into reeled silk is the next major step in transforming our spider silk technology into commercially available yarns and fabrics. The image shared today represents only a portion of what has already been processed, and we remain on pace to complete this work in line with our broader production strategy.”

This milestone represents another breakthrough in the Company’s strategy to establish the world’s first and only reliable, commercially scalable, and cost-effective supply chain for spider silk, nature’s super material.

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., April 20, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has begun processing nearly 1.8 metric tons of recombinant spider silk cocoons into finished reeled silk.

In early April, the Company announced that it had exceeded 1.3 metric tons of cocoon production in March, setting a new production record. Since that announcement, Kraig Labs is now confirming that it produced an additional half ton of cocoons (approximately) that were not included in the in the March report. This brings the Company’s total available cocoon inventory to nearly 1.8 metric tons. The attached image represents less than 4% of the total cocoon production.

Kraig Labs has now initiated the reeling process, converting this inventory into finished reeled silk. This work is currently underway at one of the Company’s production partners and is expected to be completed by the end of the month.

Upon completion of this processing phase, Kraig Labs expects to hold the largest inventory of recombinant spider silk in its history. To the Company’s knowledge, this volume also represents the largest single supply of recombinant spider silk ever to exist.

The finished reeled silk will shortly be available for processing, including twisting into yarns and integration into textile and technical material applications. Kraig Labs plans to make these materials available to targeted markets, including luxury fashion, performance textiles, and industrial applications.

Senior management is currently in Asia overseeing these operations. During this visit, leadership is working directly with production staff to monitor the reeling process, evaluate facility performance, and coordinate with supply chain partners. Management is also advancing the implementation of the Company’s aggressive scale-up strategy. This plan is designed to continue rapidly increasing production output in the months ahead.

“The execution we are seeing across our operations is tracking exactly as we expected,” said Kim Thompson, Founder and CEO of Kraig Labs. “That is a direct result of the considerable groundwork our team has completed over the last three years to put our production infrastructure in place and fine tune our processes in the field. What we are seeing now is preparation translating into consistent, scalable output.”

The Company leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., April 13, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that senior management is traveling to South East Asia this week to build on the momentum of its recently announced record-setting production of 1.3 metric tons of recombinant spider silk cocoons in a single month.

The visit follows the Company’s successful delivery on the aggressive production targets it outlined earlier this year. The 1.3 metric ton milestone represents not only a record-setting achievement but a clear validation of the Company’s execution strategy and operational scale-up model.

During the trip, management will conduct a detailed review of the most recent production cycle, including output quality, yield performance, and processing efficiency. The team will also oversee downstream processing of its recombinant spider silk cocoons into reeled silk, a critical step in transforming raw production into commercial-ready materials.

In addition, management will meet with leadership at Prodigy Silk, Kraig Labs’ subsidiary, and key representatives from the Company’s expanding production network. These meetings will focus on near-term expansion planning, strengthening coordination across the production pipeline, and identifying opportunities to further accelerate growth.

“We set a plan, we delivered, and now we are moving immediately to expand on that success,” said Kim Thompson, Founder and CEO of Kraig Labs. “This trip is about turning a major milestone into a Launchpad for what comes next.”

While achieving 1.3 metric tons marks a significant step forward, the Company emphasized that this milestone is not an endpoint but a waypoint on its near-term roadmap. Kraig Labs remains focused on rapidly advancing toward its stated goal of reaching 10 metric tons of monthly production.

“Our roadmap has always been clear,” Thompson continued. “This level of production demonstrates that our systems work, our partnerships are strong, and our strategy is sound. The work we are doing now is about scaling faster, refining processes, and closing the gap to our next major production target.”

The Company expects insights from this visit to directly inform upcoming production cycles and further strengthen its ability to scale recombinant spider silk output to unprecedented levels.

The Company leadership in bioengineering was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of its work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Record-breaking output validates aggressive scale-up strategy as Company accelerates toward 10 metric tons per month

ANN ARBOR, Mich., April 6, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has produced more than 1.3 metric tons of recombinant spider silk cocoons in a single month. This is a new world record and shatters the Company’s previous production record by a factor of five. Today marks a pivotal step forward in the transition of spider silk from laboratory innovation to an industrial-scale material platform.

When Kraig Labs unveiled its 2026 production plan in February, the Company committed to an aggressive timeline to scale spider silk output to multi-ton commercial volumes. Today’s announcement confirms that Kraig Labs is delivering on that commitment.

“This is a defining moment for our Company and for the future of advanced materials. We told the market we were going to scale fast, and that is exactly what we are doing,” said Kim Thompson, Founder and CEO of Kraig Labs. “Crossing the one metric ton mark in a single month is a massive commercialization milestone. This is real production at scale. Recombinant spider silk commercialization isn’t coming, it’s here.”

The Company reported that the production ramp was completed without operational disruptions or delays. Expanded facilities and newly deployed BAM-1 Alpha production hybrids performed as designed, with output meeting or exceeding internal benchmarks at every stage. This seamless execution reflects years of investment in scalable infrastructure, proprietary production strains, and vertically integrated operations.

Each phase of the Company’s scale-up has now been validated in the field, building a foundation for continued acceleration.

“This wasn’t a one-off. This was a pressure test of our entire system, our facilities, our hybrids, our team, and every piece delivered,” Thompson added. “We built this platform and a technology designed for scale, and the results speak for themselves.”

With the one metric ton threshold now cleared, Kraig Labs is driving toward its next major target: 10 metric tons of spider silk cocoon production per month. The Company expects to reach that level within the coming months, unlocking significant commercial opportunities across technical textiles, performance apparel, and other applications.

At that scale, Kraig Labs believes spider silk will move from a breakthrough biomaterial to a widely available, high-performance industrial fiber. A material that has no equal; lightweight, exceptionally strong, and sustainably produced.

“Our trajectory is accelerating,” Thompson concluded. “We are building something the world has never seen before, and we’re doing it faster than most thought possible.”

The Company leadership in bioengineering was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of its work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., March 30, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced the successful deployment of more than 700,000 BAM-1 Alpha production hybrids of its previously reported 1,000,000 egg inventory.  These silkworms are now in active production. This achievement underscores the Company’s continued execution of its previously announced plan for rapid production expansion of recombinant spider silk. The Company seeks to increase output to metric ton levels.

In February, Kraig Labs outlined an aggressive pathway to dramatically increase recombinant spider silk production. Today’s announcement confirms that the Company is solidly on track, having achieved a key milestone by releasing more than 700,000 production hybrids in a single month.

“This is exactly the kind of disciplined, structured, and milestone-driven execution we set out to achieve,” said Kim Thompson, Founder and CEO of Kraig Labs. “We laid out an ambitious plan to scale production to unprecedented levels, and we are now systematically delivering against that roadmap. The rapid deployment of more than 700,000 BAM-1 Alpha hybrids represents a major step forward as we move toward our goal of producing spider silk at metric ton levels.”

Kraig’s production team has reported that the BAM-1 Alpha hybrids are performing exceptionally well, exceeding internal expectations for robustness and productivity. These results further validate the Company’s decision to center its scale-up strategy around the BAM-1 Alpha platform.

Kraig Labs has emphasized a systematic, milestone-based approach to achieving its long-term production targets. Each phase of expansion is designed to build upon prior successes, ensuring stability and repeatability as output increases.

With the successful deployment of this latest production run, the Company continues to advance toward its objectives. Management believes that its current trajectory positions the Company to achieve this target on an accelerated timeline.

“We see these results as a clear demonstration that our strategy is working,” Thompson added. “We are executing an aggressive plan, hitting our milestones, and moving with purpose toward industrial-scale commercial spider silk production.”

______________________________________________________________________

The Company’s leadership in bioengineering was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of its work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., March 23, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced a significant expansion of its research and development capacity designed to keep pace with rapid progress of its advanced materials initiative, Project Atlas.

The Company has expanded its laboratory capabilities, onboarding new scientific personnel and the deployment of new advanced equipment. These improvements have roughly tripled screening throughput, allowing the R&D team to keep up with the rapid development of new transgenics.

Kraig Labs implemented these upgrades in direct response to the rapid technical progress made under Project Atlas. Atlas is the Company’s next-generation recombinant spider silk program focused on creating advanced biomaterials with potential industrial and defense applications.

The recently commissioned equipment streamlines the screening of newly created transgenic lines and the analysis of their resulting spider silk expression levels. Project Atlas is now generating significant numbers of transgenics and potential candidates for new production materials. This expanded screening capacity was needed to keep pace with the rate of new transgenic creation, which is now at the highest levels in the Company’s history. By automating portions of the testing workflow, Kraig Labs can now rapidly process and evaluate significantly more samples, quickly identifying new, exciting transgenics.

In addition to the increased screening capacity, Kraig Labs also strengthened its analytical testing capabilities. These tools provide deeper insight into the expression levels and functional impact of each engineered transgenic line. This enhanced visibility allows the research team to identify the most promising genetic designs and prioritize them for advancement into the Company’s production pipeline.

“With the pace of discovery we are seeing in Project Atlas, it became clear that we needed to expand our screening and analysis capacity to keep up with the speed of innovation,” said Kim Thompson, Founder and CEO of Kraig Labs. “This investment in staff and technology further strengthens our position as a leader in advanced biomaterials. We believe we have a wide lead on our competitors, and it is the goal of this investment to expand that lead further.”

Dr. Zhang, the Company’s Chief Scientist, emphasized the impact these upgrades will have on the research pipeline.

“Project Atlas involves the creation and evaluation of numerous complex genetic constructs designed to work together to produce highly specialized silk proteins,” said Dr. Zhang. “The expansion of our testing infrastructure dramatically increases our testing capacity to match the increased pace of transgenic creation. We can now analyze many more transgenic lines in parallel and better quantify how each genetic insert is performing. This level of screening power is essential for isolating the highest-performing lines and rapidly advancing them into production.”

By significantly increasing screening capacity and analytical insight, Kraig Labs expects to shorten development timelines and improve its ability to identify breakthrough material candidates.

The Company leadership in bioengineering was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of its work scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com